About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 1NCT00632424

Phase 1 Trial of Oral Ixabepilone

This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosin...

Lead sponsor: R-Pharm•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

R-Pharm

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Males and females, 18 or older
•Histologically or cytologically confirmed diagnosis of solid tumor malignancy
•Measurable or non-measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
•Karnofsky Performance Status (KPS) of 70-100
•Recovered from toxicities resulting from previous therapies

Exclusion Criteria

•More than 3 prior cytotoxic regimens in the metastatic setting
•Current or recent gastrointestinal (GI) disease that would impact the absorption of study drug
•Inability to swallow whole capsules
•Inadequate hepatic and renal function
•Function exposure to any epothilone

Related studies

RECRUITINGPhase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937 · Small Cell Lung Cancer, Melanoma, and more

RECRUITINGPhase 1

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

NCT07387068 · Advanced Solid Tumors

RECRUITINGPhase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

NCT07360314 · Advanced Solid Tumors

RECRUITINGPhase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

NCT07403721 · Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

RECRUITINGPhase 1

A Study of HDM2024 in Participants With Advanced Solid Tumors

NCT07539285 · Advanced Solid Tumors

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 10, 2016Terms

Trial snapshot

StatusTERMINATED

PhasePHASE1

Enrollment23

Start dateMay 2008

Last updatedMar 10, 2016

Condition

Advanced Solid Tumors

Locations shown

Stanford University

Stanford, California

Georgetown University Medical Center

Washington D.C., District of Columbia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2016Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions